What is Leucine?
Founded in 2019 and headquartered in Wilmington, Delaware, Leucine offers a no-code software platform designed to streamline compliance and audit readiness for pharmaceutical manufacturers. The solution empowers Manufacturing, QA, and QC teams to embed compliance directly into their workflows, covering critical processes from material receipt to batch release. Globally, pharmaceutical facilities leverage Leucine's capabilities to elevate product quality, operational efficiency, and sustainability.
How much funding has Leucine raised?
Leucine has raised a total of $7M across 1 funding round:
Series A
$7M
Series A (2023): $7M with participation from Ecolab
Key Investors in Leucine
Ecolab
Ecolab is a global leader in water, hygiene, and infection prevention solutions, partnering with various industries including manufacturing to deliver comprehensive programs that enhance safety, efficiency, and sustainability. Their involvement suggests a strategic alignment with Leucine's mission to improve operational standards in regulated environments.
What's next for Leucine?
The recent major strategic investment signals a period of accelerated growth and market expansion for Leucine. With this substantial backing, the company is poised to further develop its no-code compliance platform, potentially enhancing its feature set to address an even broader spectrum of regulatory challenges in pharmaceutical manufacturing. Future endeavors will likely focus on deepening its market penetration, forging new strategic partnerships, and continuing to innovate in the critical area of regulatory technology, solidifying its position as a leader in the no-code compliance software space.
See full Leucine company page
